Inmune Bio (INMB) Payables (2017 - 2025)
Inmune Bio's Payables history spans 9 years, with the latest figure at $25000.0 for Q3 2025.
- For Q3 2025, Payables fell 99.76% year-over-year to $25000.0; the TTM value through Sep 2025 reached $25000.0, down 99.76%, while the annual FY2024 figure was $25000.0, 99.68% down from the prior year.
- Payables for Q3 2025 was $25000.0 at Inmune Bio, roughly flat from $25000.0 in the prior quarter.
- Across five years, Payables topped out at $10.6 million in Q3 2024 and bottomed at $9000.0 in Q2 2021.
- The 5-year median for Payables is $1.7 million (2022), against an average of $3.3 million.
- The largest annual shift saw Payables surged 18644.44% in 2022 before it plummeted 99.76% in 2025.
- A 5-year view of Payables shows it stood at $199000.0 in 2021, then soared by 2516.08% to $5.2 million in 2022, then skyrocketed by 51.77% to $7.9 million in 2023, then crashed by 99.68% to $25000.0 in 2024, then changed by 0.0% to $25000.0 in 2025.
- Per Business Quant, the three most recent readings for INMB's Payables are $25000.0 (Q3 2025), $25000.0 (Q2 2025), and $7.2 million (Q1 2025).